Scope, Claims, and Patent Landscape of U.S. Patent 8,021,335
What does U.S. Patent 8,021,335 cover?
U.S. Patent 8,021,335, granted on September 20, 2011, is held by Pacific Biosciences of California, Inc. It claims an invention related to methods of DNA sequencing using real-time detection of nucleotide incorporation, specifically via single-molecule, real-time (SMRT) sequencing technology.
The patent's core claims focus on enzymatic processes for sequencing DNA, involving a DNA polymerase that incorporates nucleotides into a DNA strand while being detected optically in real time. The invention enables direct, long-read sequencing with high accuracy, significantly advancing next-generation sequencing capabilities.
Key elements of the claims:
- A method involving providing a DNA polymerase attached to a substrate.
- Introducing nucleotide triphosphates (dNTPs) labeled with detectable markers.
- Detecting the incorporation of nucleotides during DNA synthesis in real time.
- Using optical detection to identify specific nucleotides based on emitted signals.
The patent encompasses various embodiments, including different types of detectable labels and specific enzyme configurations. It emphasizes the use of fluorescent labels and specific hardware arrangements for optical detection.
How broad are the claims?
The claims primarily focus on the enzymatic process of real-time DNA sequencing and the detection of nucleotide incorporation via fluorescence. The scope extends to:
- A range of detectable labels, including different fluorescent dyes.
- Various configurations of the enzyme and substrate apparatus.
- Methods for sequencing individual DNA molecules.
The claims do not broadly cover all possible sequencing methods but are specific to SMRT sequencing systems that use fluorescence detection during DNA synthesis.
Limitations of the claims:
- The claims are limited to methods involving specific enzymatic processes and optical detection techniques.
- They do not claim alternative sequencing methods such as nanopore or electrical detection.
- The patent does not extend to downstream data analysis or purely computational methods.
How does it compare with existing patents?
At the time of issuance, U.S. Patent 8,021,335 represented a significant advancement over prior art, including:
- Classical sequencing methods like Sanger sequencing, which are slower and less scalable.
- Early next-generation sequencing methods that lack real-time detection or single-molecule resolution.
This patent's claims are more specific than older sequencing patents, providing protection primarily for the techniques involving real-time fluorescence detection at the single-molecule level.
Patent landscape surrounding 8,021,335
Related patents and applications
The patent is part of a broader portfolio held by Pacific Biosciences, which includes several patents and applications covering:
- Polymerase enzyme engineering.
- Optical detection systems.
- Sample preparation methods.
Key related patents include:
- U.S. Patent 8,248,542: Methods involving different nucleotide labeling configurations.
- U.S. Patent 8,491,761: Improvements in enzyme stability and sequencing accuracy.
Competitor landscape
Companies active in the field include Illumina, Oxford Nanopore Technologies, and Bionano Genomics, which focus on different sequencing modalities. Illumina’s core patents cover sequencing by synthesis methods lacking single-molecule real-time detection. Oxford Nanopore holds patents on nanopore sequencing, distinct from SMRT.
Patent challenges or licensing concerns:
- Pacific Biosciences has engaged in licensing arrangements with other firms to enforce rights related to this technology.
- Competitors seek alternative methods that do not infringe on claims specific to fluorescence-based SMRT sequencing.
Recent patent filings
Between 2010 and 2015, many patent applications filed by Pacific Biosciences expand on the methods disclosed in 8,021,335, including improvements on detection chemistry, enzyme engineering, and hardware design.
Patent lifecycle and legal status
The patent was filed on May 19, 2010, and granted on September 20, 2011, with a term extending until May 19, 2030, assuming all maintenance fees are paid.
Legal status:
- The patent remains active.
- No substantial opposition or invalidation proceedings are publicly recorded.
Implications for R&D and commercialization
The scope of U.S. Patent 8,021,335 limits its infringement primarily to companies employing fluorescence-based real-time sequencing methods utilizing similar enzyme and detection configurations. Its broad claims concerning enzymatic processes and detection methods give Pacific Biosciences a defensible position in licensing negotiations. The patent landscape reflects a robust innovation environment with overlapping and complementary IP assets.
Key Takeaways
- U.S. Patent 8,021,335 claims methods for real-time, single-molecule DNA sequencing with fluorescence detection.
- The patent's scope covers specific enzymatic processes and optical detection techniques.
- The patent landscape includes numerous related patents by Pacific Biosciences, focusing on improvements in sequencing chemistry, enzyme stability, and hardware.
- Major competitors operate on different sequencing principles, reducing direct infringement risks.
- The patent remains active and influential for the commercialization of SMRT sequencing technology.
FAQs
1. Does U.S. Patent 8,021,335 cover all DNA sequencing technologies?
No. It specifically covers real-time, fluorescence-based single-molecule sequencing methods. Other techniques like nanopore sequencing are outside its scope.
2. Can a company develop sequencing methods using non-fluorescent detection systems without infringing?
Yes. The patent claims are specific to fluorescence detection systems. Non-fluorescent methods such as electrical detection do not fall under its scope.
3. Are the claims limited to specific chemistries or configurations?
The claims are broad but focus on enzymatic incorporation and optical detection. Alternative labels and enzyme setups are covered, but the core concepts are defined.
4. How does this patent impact licensing negotiations?
It enables Pacific Biosciences to enforce their rights on SMRT sequencing methods, potentially licensing their IP to competitors or collaborators adopting similar techniques.
5. What future patent filings could affect the scope of this patent?
Continued innovations in sequencing chemistry, detection hardware, and data processing methods by Pacific Biosciences or competitors could lead to new patent applications that expand or narrow the existing landscape.
References
[1] U.S. Patent 8,021,335. (2011). Methods of DNA sequencing using real-time detection. Patent and Trademark Office.
[2] Harris, S. A., et al. (2014). Advancements in single-molecule DNA sequencing. Nature Biotechnology, 32(9), 962-964.
[3] Pacific Biosciences. (2015). Patent portfolio and licensing strategy. Company filings.
